Summary information and primary citation
- PDB-id
- 7l1f; SNAP-derived features in text and JSON formats;
DNAproDB
- Class
- viral protein-RNA
- Method
- cryo-EM (3.89 Å)
- Summary
- Sars-cov-2 rdrp in complex with 4 remdesivir monophosphate
- Reference
- Bravo JPK, Dangerfield TL, Taylor DW, Johnson KA (2021): "Remdesivir is a delayed translocation inhibitor of SARS-CoV-2 replication." Mol.Cell, 81, 1548-1552.e4. doi: 10.1016/j.molcel.2021.01.035.
- Abstract
- Remdesivir is a nucleoside analog approved by the US FDA for treatment of COVID-19. Here, we present a 3.9-Å-resolution cryo-EM reconstruction of a remdesivir-stalled RNA-dependent RNA polymerase complex, revealing full incorporation of 3 copies of remdesivir monophosphate (RMP) and a partially incorporated fourth RMP in the active site. The structure reveals that RMP blocks RNA translocation after incorporation of 3 bases following RMP, resulting in delayed chain termination, which can guide the rational design of improved antiviral drugs.